28165155|t|Performance of ANTI-HCV testing in dried blood spots and saliva according to HIV status
28165155|a|The use of saliva and dried blood spots (DBS) could increase access to HCV diagnosis for high-risk populations, such as HIV-infected individuals, but the performance of these assays has not been well established in this group. This study aims to evaluate HIV status, particularly TCD4(+) cell count and viral load, in the performance of anti-HCV testing using DBS and saliva. A total of 961 individuals classified as HCV+, HIV+, or HIV / HCV+, as well as negative controls, donated serum, DBS, and saliva samples for anti-HCV testing using a commercial enzyme immunoassay. Sample volume was modified for DBS and saliva, and an ROC curve was used for cut-off determination in saliva. Anti-HCV sensitivities were greater than 93% using DBS and saliva in the HCV+ group, while they were 83.3% and 95.6% for HCV / HIV+ individuals for DBS and saliva assays, respectively. Specificity varied from 91.7% to 100% using saliva and DBS in HIV monoinfected and control subjects. When only anti-HCV / HCV RNA+ serum samples, that is, true positives, were considered, the sensitivities were 98.3% and 100% for DBS and saliva, respectively, in the HCV+ group and 91.6% and 94.8% for DBS and saliva, respectively, in the HIV / HCV+ group. High absorbance values were observed among those presenting with HCV RNA in serum and low HIV viral load (less than 50 copies/mL). In conclusion, DBS and saliva samples could be used for anti-HCV detection, particularly to identify active HCV cases, but low sensitivity was observed for anti-HCV testing using DBS in the HIV / HCV+ group.
28165155	0	11	Performance	T052	C1882330
28165155	15	31	ANTI-HCV testing	T059	C0201487
28165155	35	52	dried blood spots	T031	C3830395
28165155	57	63	saliva	T031	C0036087
28165155	77	87	HIV status	T033	C0458074
28165155	99	105	saliva	T031	C0036087
28165155	110	127	dried blood spots	T031	C3830395
28165155	129	132	DBS	T031	C3830395
28165155	140	148	increase	T169	C0442805
28165155	149	155	access	T169	C1554204
28165155	159	162	HCV	T047	C4288963
28165155	163	172	diagnosis	T033	C0011900
28165155	177	198	high-risk populations	T098	C0870646
28165155	208	220	HIV-infected	T047	C0019693
28165155	221	232	individuals	T098	C0237401
28165155	242	253	performance	T052	C1882330
28165155	263	269	assays	T059	C1510438
28165155	308	313	group	T078	C0441833
28165155	334	342	evaluate	T058	C0220825
28165155	343	353	HIV status	T033	C0458074
28165155	368	380	TCD4(+) cell	T025	C0039215
28165155	381	386	count	T059	C0007584
28165155	391	401	viral load	T059	C1168369
28165155	410	421	performance	T052	C1882330
28165155	425	441	anti-HCV testing	T059	C0201487
28165155	448	451	DBS	T031	C3830395
28165155	456	462	saliva	T031	C0036087
28165155	479	490	individuals	T098	C0237401
28165155	505	509	HCV+	T034	C2748185
28165155	511	515	HIV+	T034	C2748218
28165155	520	523	HIV	T034	C2748218
28165155	526	530	HCV+	T034	C2748185
28165155	543	560	negative controls	T077	C1947986
28165155	570	575	serum	T031	C0229671
28165155	577	580	DBS	T031	C3830395
28165155	586	600	saliva samples	T031	C0438730
28165155	605	621	anti-HCV testing	T059	C0201487
28165155	641	659	enzyme immunoassay	T059	C0086231
28165155	661	674	Sample volume	T034	C1318073
28165155	679	687	modified	T169	C0392747
28165155	692	695	DBS	T031	C3830395
28165155	700	706	saliva	T031	C0036087
28165155	715	724	ROC curve	T081	C0035787
28165155	738	745	cut-off	T169	C1442160
28165155	746	759	determination	T059	C1148554
28165155	763	769	saliva	T031	C0036087
28165155	771	779	Anti-HCV	T116,T129	C0166049
28165155	780	793	sensitivities	T080	C1522640
28165155	822	825	DBS	T031	C3830395
28165155	830	836	saliva	T031	C0036087
28165155	844	848	HCV+	T034	C2748185
28165155	849	854	group	T078	C0441833
28165155	892	895	HCV	T034	C2748185
28165155	898	902	HIV+	T034	C2748218
28165155	903	914	individuals	T098	C0237401
28165155	919	922	DBS	T031	C3830395
28165155	927	933	saliva	T031	C0036087
28165155	934	940	assays	T059	C1510438
28165155	956	967	Specificity	T044	C0003264
28165155	1000	1006	saliva	T031	C0036087
28165155	1011	1014	DBS	T031	C3830395
28165155	1018	1034	HIV monoinfected	T047	C0019693
28165155	1039	1055	control subjects	T096	C0009932
28165155	1067	1075	anti-HCV	T116,T129	C0166049
28165155	1078	1086	HCV RNA+	T034	C0855842
28165155	1087	1100	serum samples	T031	C1550100
28165155	1111	1125	true positives	T080	C0205559
28165155	1148	1161	sensitivities	T080	C1522640
28165155	1186	1189	DBS	T031	C3830395
28165155	1194	1200	saliva	T031	C0036087
28165155	1223	1227	HCV+	T034	C2748185
28165155	1228	1233	group	T098	C1257890
28165155	1258	1261	DBS	T031	C3830395
28165155	1266	1272	saliva	T031	C0036087
28165155	1295	1298	HIV	T034	C2748218
28165155	1301	1305	HCV+	T034	C2748185
28165155	1306	1311	group	T098	C1257890
28165155	1313	1317	High	T080	C0205250
28165155	1318	1328	absorbance	T201	C1268822
28165155	1329	1335	values	T081	C1522609
28165155	1341	1349	observed	T169	C1441672
28165155	1378	1385	HCV RNA	T059	C1868902
28165155	1389	1394	serum	T031	C0229671
28165155	1399	1402	low	T080	C0205251
28165155	1403	1417	HIV viral load	T059	C1168369
28165155	1459	1462	DBS	T031	C3830395
28165155	1467	1481	saliva samples	T031	C0438730
28165155	1500	1508	anti-HCV	T116,T129	C0166049
28165155	1509	1518	detection	T061	C1511790
28165155	1545	1551	active	T169	C0205177
28165155	1552	1555	HCV	T047	C4288963
28165155	1556	1561	cases	T169	C0868928
28165155	1567	1570	low	T080	C0205251
28165155	1571	1582	sensitivity	T080	C1522640
28165155	1587	1595	observed	T169	C1441672
28165155	1600	1616	anti-HCV testing	T059	C0201487
28165155	1623	1626	DBS	T031	C3830395
28165155	1634	1637	HIV	T034	C2748218
28165155	1640	1644	HCV+	T034	C2748185
28165155	1645	1650	group	T098	C1257890